Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 11, 2022

SELL
$13.13 - $24.52 $264,989 - $494,862
-20,182 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$21.01 - $27.64 $18,803 - $24,737
895 Added 4.64%
20,182 $519,000
Q2 2021

Aug 12, 2021

BUY
$23.49 - $35.8 $453,051 - $690,474
19,287 New
19,287 $503,000

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $418M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Bank Of Nova Scotia Portfolio

Follow Bank Of Nova Scotia and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Nova Scotia, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Nova Scotia with notifications on news.